NASDAQ:ARDX - Ardelyx Stock Price, Forecast & News

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Ardelyx Inc (NASDAQ:ARDX) posted its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.37). The biopharmaceutical company earned $3.01 million during the quarter. View Ardelyx's Earnings History.

Ardelyx is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Ardelyx.

6 Wall Street analysts have issued 1 year target prices for Ardelyx's stock. Their forecasts range from $9.00 to $15.00. On average, they expect Ardelyx's stock price to reach $11.40 in the next year. This suggests a possible upside of 58.3% from the stock's current price. View Analyst Price Targets for Ardelyx.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ardelyx.

News stories about ARDX stock have trended somewhat positive on Monday, according to InfoTrie. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ardelyx earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Ardelyx.

Ardelyx saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 3,940,000 shares, an increase of 42.8% from the December 31st total of 2,760,000 shares. Based on an average daily trading volume, of 890,800 shares, the short-interest ratio is currently 4.4 days. Approximately 6.3% of the shares of the stock are sold short. View Ardelyx's Current Options Chain.

Some companies that are related to Ardelyx include Forty Seven (FTSV), Ironwood Pharmaceuticals (IRWD), Heron Therapeutics (HRTX), Aimmune Therapeutics (AIMT), Arvinas (ARVN), Akcea Therapeutics (AKCA), Alder Biopharmaceuticals (ALDR), Innoviva (INVA), Corcept Therapeutics (CORT), Constellation Pharmaceuticals (CNST), Amneal Pharmaceuticals (AMRX), Dicerna Pharmaceuticals (DRNA), BELLUS Health (BLUSF), Endo International (ENDP) and IGM Biosciences (IGMS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX), BioCryst Pharmaceuticals (BCRX), ImmunoGen (IMGN), Idera Pharmaceuticals (IDRA), SCYNEXIS (SCYX) and Synergy Pharmaceuticals (SGYP).

Ardelyx's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (24.52%), RA Capital Management L.P. (8.14%), Renaissance Technologies LLC (3.74%), Marshall Wace LLP (1.74%), State Street Corp (1.35%) and Ikarian Capital LLC (0.98%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Gordon Ringold, Mark Kaufmann, Michael Raab and Scott D Sandell. View Institutional Ownership Trends for Ardelyx.

ARDX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Jacobs Levy Equity Management Inc., Tower Research Capital LLC TRC , Blair William & Co. IL and Citigroup Inc.. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Mark Kaufmann and Michael Raab. View Insider Buying and Selling for Ardelyx.

ARDX stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Marshall Wace LLP, NEA Management Company LLC, Ikarian Capital LLC, J. Goldman & Co LP, Bailard Inc., FMR LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Ardelyx.

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARDX stock can currently be purchased for approximately $7.20.

Ardelyx has a market capitalization of $473.76 million and generates $2.61 million in revenue each year. The biopharmaceutical company earns $-91,300,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Ardelyx employs 86 workers across the globe.View Additional Information About Ardelyx.

The official website for Ardelyx is http://www.ardelyx.com/.

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]